论文部分内容阅读
化学名 6-[4-(1-环己基-1H-四唑基-5)丁氧基]一3,4-二H-2(1H)-喹啉酮药效分类抗血小板药开发单位 (日本)大塚制药公司上市厂商 (日本)大塚制药公司,1988年1月20日药理在人和动物血液中,本品能明显抑制各种聚集诱导剂引起的血小板聚集,且可使聚集块解离,不引起二次聚集。主要代谢产物环氧化物的活性为原药的3～4倍。本品对胶原、ADP,花生四烯酸、月桂酸钠引起脑循环及末梢循环障碍的模型有明显的抗血栓作用。
Chemical Name 6- [4- (1-Cyclohexyl-1H-tetrazolyl-5) butoxy] -3,4-dihvdro-2 (1H) -quinolinone Pharmacodynamic Category Anti- Japan) Otsuka Pharmaceutical Co., Ltd. (Japan) Otsuka Pharmaceutical Co., Ltd., January 20, 1988 Pharmacology In human and animal blood, this product can significantly inhibit platelet aggregation induced by various aggregation inducing agents and can dissociate aggregates , Does not cause secondary aggregation. The activity of the major metabolite epoxide is 3 to 4 times that of the original drug. This product of collagen, ADP, arachidonic acid, sodium laurate caused by cerebral circulation and peripheral circulation disorders model has a significant anti-thrombotic effect.